ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Cancer Research

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-2352PMID 16467117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

  2005cited by this paper
• Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

  2005cited by this paper
• Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.

  2005cited by this paper
• Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.

  2005cited by this paper
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005cited by this paper
• Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.

  2003cited by this paper
• Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

  2003cited by this paper
• ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.

  2003cited by this paper
• Autocrine Transforming Growth Factor-β Signaling Mediates Smad-independent Motility in Human Cancer Cells*

  2003cited by this paper
• ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

  2003cited by this paper
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer

  2003cited by this paper
• Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.

  2003cited by this paper
• Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone‐dependent breast cancer cells

  2002cited by this paper
• ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27-Haploinsufficient Mammary Epithelial Cells but Impaired in p27-Null Cells

  2002cited by this paper
• Endocrine-responsive breast cancer and strategies for combating resistance

  2002cited by this paper
• Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

  2001cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.

  2001cited by this paper
• Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

  2001cited by this paper
• Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

  2001cited by this paper
• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Aromatase inhibitors in the treatment and prevention of breast cancer.

  2001cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

  2000cited by this paper
• Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo.

  2000cited by this paper
• The ErbB signaling network: receptor heterodimerization in development and cancer

  2000cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Aromatase inhibitors and their antitumor effects in model systems.

  1999cited by this paper
• The effects of aromatase inhibitors and antiestrogens in the nude mouse model

  1998cited by this paper
• Tamoxifen for Prevention of Breast Cancer.

  1998cited by this paper
• Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

  1998cited by this paper
• In situ aromatization enhances breast tumor estradiol levels and cellular proliferation.

  1998cited by this paper
• Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells.

  1998cited by this paper
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  1992cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Transforming Growth Factor (cid:2) (TGF- (cid:2) )-Smad Target Gene Protein Tyrosine Phosphatase Receptor Type Kappa Is Required for TGF- (cid:2) Function†

  year unknowncited by this paper

• Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

  2026cites this paper
• Long-term survival outcomes of neoadjuvant chemotherapy in stage II-III HR+/HER2- breast cancer

  2025cites this paper
• Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

  2024cites this paper
• The genomic landscape associated with resistance to aromatase inhibitors in breast cancer

  2023cites this paper
• Targeted therapy for breast cancer: An overview of drug classes and outcomes.

  2022cites this paper
• Endocrine Therapy for Hormone Receptor‐Positive Breast Cancer

  2019cites this paper
• IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

  2017cites this paper
• Treatment of Metastatic Breast Cancer: Endocrine Therapy

  2016cites this paper
• Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.

  2016cites this paper
• Aromatase inhibitors in breast cancer: Signaling pathways involved in exemestane-acquired resistance

  2016influential citation
• Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer

  2015cites this paper
• Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review

  2015cites this paper
• Resistance to Aromatase Inhibitors in Breast Cancer

  2015cites this paper
• Optimizing the Use of Neoadjuvant Endocrine Therapy

  2015cites this paper
• Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer

  2014cites this paper
• Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer

  2014cites this paper
• QuantitativeERandPgRAssessmentasPredictorsofBene fi t from Lapatinib in Postmenopausal Women with Hormone Receptor – Positive , HER 2-Negative Metastatic Breast Cancer

  2014cites this paper
• Emerging strategies to overcome resistance to endocrine therapy for breast cancer

  2014cites this paper
• Breast cancer: Current and future endocrine therapies

  2014cites this paper
• Title : Proteomic Classification of Breast Cancer

  2013cites this paper
• Breast Cancer MicroRNAs: Signaling Networks and Clinical Applications

  2013cites this paper
• Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

  2013cites this paper
• AIB1:ERa Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells

  2012cites this paper
• Proteomic classification of breast cancer.

  2012cites this paper
• AIB1:ERα Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor–Resistant Breast Cancer Cells

  2012cites this paper
• AIB1: A Transcriptional Coactivator Which Integrates Signaling Cross Talk in Cancer Cells

  2012cites this paper
• AIB1:ERalpha transcriptional activity is selectively enhanced in AI-resistant breast cancer cells

  2012cites this paper
• Les cancers du sein HER2 : que devons-nous retenir dans notre pratique clinique quotidienne ?

  2011cites this paper
• The therapy interfering EGFR activation in breast cancer patients

  2011cites this paper
• Leczenie interferujące z funkcją EGFR u chorych na raka piersi

  2011cites this paper
• Significance of ER-Src axis in hormonal therapy resistance

  2011cites this paper
• Significance of ER–Src axis in hormonal therapy resistance

  2011cites this paper
• [Her2 positive breast cancer: practices].

  2011cites this paper
• Lapatinib: new opportunities for management of breast cancer.

  2010cites this paper
• Regulation of aromatase induction by nuclear receptor coregulator PELP1.

  2010cites this paper
• Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling

  2010cites this paper
• Award Number: W81XWH-08-1-0604 TITLE: Hormonal Resistance and Metastasis: ER-coregulator-Src Signaling Targeted therapy

  2010cites this paper
• Lapatinib

  2010cites this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cites this paper
• Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

  2009cites this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cites this paper
• Hormonal Resistance and Metastasis: ER-coregulator-Src Targeted Therapy

  2009cites this paper
• The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer

  2009cites this paper
• Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.

  2009cites this paper
• Natural products as aromatase inhibitors.

  2008cites this paper
• Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells.

  2008cites this paper
• 589 POSTER Functional evaluation of members of the LIV-1 family of proteins and their role in breast cancer

  2008cites this paper
• The Impact of ErbB2 on Cancer Progression and Metastasis through Modulation of Tumor and Tumor Microenvironment

  2008cites this paper
• Role of PELP1 in EGFR-ER Signaling Crosstalk in Ovarian Cancer Cells

  2008cites this paper
• Wwox Suppresses Prostate Cancer Cell Growth through Modulation of ErbB2-Mediated Androgen Receptor Signaling

  2007cites this paper
• Femara® and the future: tailoring treatment and combination therapies with Femara

  2007cites this paper
• Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer

  2007cites this paper
• Aromatase inhibitors in post-menopausal metastatic breast carcinoma

  2007cites this paper
• Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis.

  2007cites this paper
• Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.

  2006cites this paper
• Expression of active Akt protects against tamoxifen‐induced apoptosis in MCF‐7 Cells

  2006cites this paper
• Sequential Adjuvant Hormone Therapy in Postmenopausal Breast Cancer: Rationale and Clinical Results

  2006cites this paper
• Sequential adjuvant hormone therapy in postmenopausal breast cancer: rationale and clinical results.

  2006cites this paper